The Theranostic Genome
Abstract Theranostic drugs represent an emerging path to deliver on the promise of precision medicine. However, bottlenecks remain in characterizing theranostic targets, identifying theranostic lead compounds, and tailoring theranostic drugs. To overcome these bottlenecks, we present the Theranostic...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-55291-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559262219730944 |
|---|---|
| author | Xiaoying Xu Pablo Jané Vincent Taelman Eduardo Jané Rebecca A. Dumont Yonathan Garama Francisco Kim María del Val Gómez Karim Gariani Martin A. Walter |
| author_facet | Xiaoying Xu Pablo Jané Vincent Taelman Eduardo Jané Rebecca A. Dumont Yonathan Garama Francisco Kim María del Val Gómez Karim Gariani Martin A. Walter |
| author_sort | Xiaoying Xu |
| collection | DOAJ |
| description | Abstract Theranostic drugs represent an emerging path to deliver on the promise of precision medicine. However, bottlenecks remain in characterizing theranostic targets, identifying theranostic lead compounds, and tailoring theranostic drugs. To overcome these bottlenecks, we present the Theranostic Genome, the part of the human genome whose expression can be utilized to combine therapeutic and diagnostic applications. Using a deep learning-based hybrid human-AI pipeline that cross-references PubMed, the Gene Expression Omnibus, DisGeNET, The Cancer Genome Atlas and the NIH Molecular Imaging and Contrast Agent Database, we bridge individual genes in human cancers with respective theranostic compounds. Cross-referencing the Theranostic Genome with RNAseq data from over 17’000 human tissues identifies theranostic targets and lead compounds for various human cancers, and allows tailoring targeted theranostics to relevant cancer subpopulations. We expect the Theranostic Genome to facilitate the development of new targeted theranostics to better diagnose, understand, treat, and monitor a variety of human cancers. |
| format | Article |
| id | doaj-art-0b5f03c23425498ba3d075cfbf0401f4 |
| institution | Kabale University |
| issn | 2041-1723 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj-art-0b5f03c23425498ba3d075cfbf0401f42025-01-05T12:36:08ZengNature PortfolioNature Communications2041-17232024-12-0115111210.1038/s41467-024-55291-xThe Theranostic GenomeXiaoying Xu0Pablo Jané1Vincent Taelman2Eduardo Jané3Rebecca A. Dumont4Yonathan Garama5Francisco Kim6María del Val Gómez7Karim Gariani8Martin A. Walter9University of LucerneUniversity of GenevaUniversity of LucerneDepartamento de Matemática Aplicada a la Ingeniería Aeroespacial - ETSIAE, Universidad Politécnica de MadridUniversity of LucerneUniversity of LucerneUniversity of LucerneServicio de Medicina Nuclear, Hospital Universitario Ramón y CajalDivision of Endocrinology, Diabetes, Nutrition and Patient Therapeutic Education, Geneva University HospitalsUniversity of LucerneAbstract Theranostic drugs represent an emerging path to deliver on the promise of precision medicine. However, bottlenecks remain in characterizing theranostic targets, identifying theranostic lead compounds, and tailoring theranostic drugs. To overcome these bottlenecks, we present the Theranostic Genome, the part of the human genome whose expression can be utilized to combine therapeutic and diagnostic applications. Using a deep learning-based hybrid human-AI pipeline that cross-references PubMed, the Gene Expression Omnibus, DisGeNET, The Cancer Genome Atlas and the NIH Molecular Imaging and Contrast Agent Database, we bridge individual genes in human cancers with respective theranostic compounds. Cross-referencing the Theranostic Genome with RNAseq data from over 17’000 human tissues identifies theranostic targets and lead compounds for various human cancers, and allows tailoring targeted theranostics to relevant cancer subpopulations. We expect the Theranostic Genome to facilitate the development of new targeted theranostics to better diagnose, understand, treat, and monitor a variety of human cancers.https://doi.org/10.1038/s41467-024-55291-x |
| spellingShingle | Xiaoying Xu Pablo Jané Vincent Taelman Eduardo Jané Rebecca A. Dumont Yonathan Garama Francisco Kim María del Val Gómez Karim Gariani Martin A. Walter The Theranostic Genome Nature Communications |
| title | The Theranostic Genome |
| title_full | The Theranostic Genome |
| title_fullStr | The Theranostic Genome |
| title_full_unstemmed | The Theranostic Genome |
| title_short | The Theranostic Genome |
| title_sort | theranostic genome |
| url | https://doi.org/10.1038/s41467-024-55291-x |
| work_keys_str_mv | AT xiaoyingxu thetheranosticgenome AT pablojane thetheranosticgenome AT vincenttaelman thetheranosticgenome AT eduardojane thetheranosticgenome AT rebeccaadumont thetheranosticgenome AT yonathangarama thetheranosticgenome AT franciscokim thetheranosticgenome AT mariadelvalgomez thetheranosticgenome AT karimgariani thetheranosticgenome AT martinawalter thetheranosticgenome AT xiaoyingxu theranosticgenome AT pablojane theranosticgenome AT vincenttaelman theranosticgenome AT eduardojane theranosticgenome AT rebeccaadumont theranosticgenome AT yonathangarama theranosticgenome AT franciscokim theranosticgenome AT mariadelvalgomez theranosticgenome AT karimgariani theranosticgenome AT martinawalter theranosticgenome |